Contribute Try STAT+ Today

Eli Lilly announced Tuesday that adding its drug Verzenio to hormone blockers decreased the risk of a relapse of breast cancer in women who had had their tumors removed.

The result makes Verzenio the first drug in its class, a group of breast cancer medicines known as CDK 4/6 inhibitors, to work in this early stage of treatment, called the adjuvant setting. The drugs are currently used in women whose breast cancer is metastatic, meaning that tumors have spread to other parts of their bodies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.